In addition, occurrence and/or co-occurrence of mutations in tumor suppressor genes like TP53 and STK11 with typical oncogene driver mutations in lung cancer have been suggested to have implications for prognosis and treatment response [30–32], which may be of complimentary clinical value. This evidence concerns the gene TP53 and lung carcinoma.